Poster presentation to highlight the design of Optimize-1, evaluating mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma
Lund, Sweden, November 12, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced that the design and scientific rationale of OPTIMIZE-1, Alligator´s phase 2 study (NCT02829099) in 1st line metastatic pancreatic cancer in combination with mFOLFIRINOX, will be presented at the Society for Immunotherapy Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs virtually on November 10th – 14th, 2021.
"Mitazalimab, a best-in-class second generation CD40 agonist, reported positive clinical data from Phase I studies, displaying a manageable safety profile, proof-of-mechanism as well as early signs of efficacy. OPTIMIZE-1 reinforces our commitment to developing mitazalimab in combination with standard of care therapies," stated Yago Pico de Coaña, PhD., Medical Science Director at Alligator Bioscience. “Targeting CD40 with mitazalimab in pancreatic ductal adenocarcinoma (PDAC), has the potential to augment responses to chemotherapy, initiating an effective anti-tumor immune response and potentially better tumor control.”
Title: OPTIMIZE-1, an open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma
Presenter: Yago Pico de Coaña, PhD.
Virtual Meeting II: E-Posters Session: Poster
For further information, please contact:
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, with MacroGenics Inc. and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.